Tuberculosis: Overview, History, Symptoms, and Prevention

Introduction | Definition | History | Transmission | Symptoms | Diagnosis | Treatment | Prevention and Control | Challenges | Future Perspectives

Introduction to Tuberculosis (TB)

Tuberculosis (TB) is one of the oldest and most persistent infectious diseases known to humanity. It is caused by the bacterium Mycobacterium tuberculosis and primarily affects the lungs, though it can also infect other organs (extrapulmonary TB). TB remains a major global health concern, particularly in low- and middle-income countries, where factors such as poverty, malnutrition, and HIV co-infection exacerbate its spread.

Despite significant advancements in medical science, TB continues to be a leading cause of death from infectious diseases worldwide. According to the World Health Organization (WHO), an estimated 10 million people fell ill with TB in 2022, and 1.3 million died from the disease. The emergence of drug-resistant strains, such as multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), has further complicated global efforts to control the disease.

This article provides a comprehensive overview of TB, including its history, definition, symptoms, diagnosis, treatment, and prevention strategies.

Definition and Causative Agent

Tuberculosis is an infectious disease caused by the acid-fast bacterium Mycobacterium tuberculosis. The bacteria grow slowly and can survive in a dormant state (latent TB) for years before becoming active.

Key Characteristics of M. tuberculosis

• Aerobic: Thrives in oxygen-rich environments (e.g., lungs).
• Acid-fast: Retains dye even after acid washing (used in diagnostic staining).
• Slow-growing: Takes weeks to culture in labs.
• Intracellular pathogen: Survives inside macrophages.

TB is classified into:

• Latent TB infection (LTBI): No symptoms, non-contagious.
• Active TB disease: Symptoms present, contagious if pulmonary.

Historical Background and Research Developments

Early Evidence of TB

TB has plagued humans for millennia. Evidence of spinal TB (Pott’s disease) has been found in Egyptian mummies dating back to 3000 BCE. Ancient Greek physicians, including Hippocrates (460–370 BCE), described a disease called phthisis (wasting disease), which was likely TB.

The 18th and 19th Centuries: Understanding TB as an Infectious Disease

Before the germ theory of disease was established, TB was thought to be hereditary or caused by environmental factors. In 1720, the English physician Benjamin Marten hypothesized that TB might be caused by “minute living creatures.” However, it was not until 1882 that German microbiologist Robert Koch identified Mycobacterium tuberculosis as the causative agent, revolutionizing the understanding of the disease.

The 20th Century: Vaccines and Antibiotics

The early 20th century saw the development of the Bacille Calmette-Guérin (BCG) vaccine (1921), which remains the only licensed TB vaccine today. The discovery of streptomycin (1944) by Selman Waksman marked the beginning of antibiotic treatment for TB. Later, other drugs such as isoniazid (1952), rifampicin (1960s), and pyrazinamide were introduced, leading to the modern Directly Observed Treatment, Short-course (DOTS) strategy.

Modern Research and Challenges

Despite these advancements, challenges such as drug resistance, HIV co-infection, and inadequate healthcare infrastructure persist. Recent research focuses on:

• Developing new vaccines (e.g., M72/AS01E candidate vaccine).
• Shorter drug regimens (e.g., BPaL for drug-resistant TB).
• Improved diagnostic tools (e.g., GeneXpert MTB/RIF assay).

Transmission of Tuberculosis

TB spreads through airborne droplets when an infected person coughs, sneezes, or talks. Key factors influencing transmission include:

• Duration of exposure (prolonged contact increases risk).
• Ventilation (poor airflow facilitates spread).
• Immune status (HIV/AIDS, diabetes, malnutrition increase susceptibility).

Not everyone exposed to TB becomes infected, and only 5–10% of infected individuals develop active TB in their lifetime.

Symptoms and Clinical Manifestations

Pulmonary TB (Lung TB) Symptoms

• Persistent cough (lasting >2–3 weeks).
• Hemoptysis (coughing up blood).
• Chest pain.
• Fever, night sweats.
• Weight loss, fatigue.

Extrapulmonary TB (Outside the Lungs)

• Lymphadenitis (TB lymphadenopathy): Swollen lymph nodes.
• Miliary TB: Widespread infection in the bloodstream.
• Spinal TB (Pott’s disease): Back pain, paralysis.
• TB meningitis: Headache, neurological symptoms.

Diagnosis of Tuberculosis

1. Microscopy and Staining

• Sputum smear microscopy (Ziehl-Neelsen stain) detects acid-fast bacilli.

2. Culture-Based Methods

• Lowenstein-Jensen medium: Gold standard but slow (4–8 weeks).

3. Molecular Tests

• GeneXpert MTB/RIF: Detects TB and rifampicin resistance in hours.
• Line probe assays (LPAs): Identify drug-resistant strains.

4. Imaging

• Chest X-ray: Shows lung abnormalities (cavities, infiltrates).

5. Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs)

• Used for latent TB detection.

Treatment and Drug Resistance

Standard Treatment Regimens

• Drug-sensitive TB: 6-month regimen (isoniazid, rifampicin, pyrazinamide, ethambutol).
• MDR-TB: 9–20 months (bedaquiline, linezolid, newer drugs).

Drug Resistance Challenges

• MDR-TB: Resistant to isoniazid and rifampicin.
• XDR-TB: Resistant to additional second-line drugs.
• Totally drug-resistant TB (TDR-TB): Almost untreatable.

Prevention and Control Measures

1. Vaccination

• BCG vaccine: Protects against severe TB in children but limited efficacy in adults.

2. Infection Control

• Isolation of infectious patients.
• Use of masks (N95 respirators).

3. Preventive Therapy

• Isoniazid preventive therapy (IPT) for latent TB.

4. Public Health Strategies

• DOTS (Directly Observed Treatment, Short-course) ensures adherence.
• WHO’s End TB Strategy (2015–2035): Aims to reduce TB deaths by 95%.

Global Burden and Current Challenges

• High-burden countries: India, China, Indonesia, Nigeria, Pakistan.
• HIV/TB co-infection: Increases mortality risk.
• Stigma and lack of awareness: Delay diagnosis and treatment.

Future Perspectives in TB Research

• New vaccines: M72/AS01E shows promise.
• Shorter drug regimens: BPaL (6-month MDR-TB treatment).
• Point-of-care diagnostics: Faster, more accessible testing.

Conclusion

Tuberculosis remains a major global health threat despite medical advancements. Combating TB requires a multifaceted approach, including better diagnostics, effective treatments, and strong public health policies. Continued research and global cooperation are essential to achieve the WHO’s goal of ending TB by 2035.